Title
Category
Credits
Event date
Cost
  • CME Activities
  • Critical Care
  • Emergency
  • Neurology
  • Nursing Continuing Education
  • Stroke
  • Tenecteplase
  • Thrombolytics
  • Nursing Education Hours
  • Participation
$0.00
Intravenous thrombolytics is the mainstay of acute therapy in ischemic stroke.  While alteplase has been FDA-approved for this indication since the 1990s, Tenecteplase has recently gained traction for usage in acute ischemic stroke treatment as well.  This lecture summarizes the existing evidence and practical considerations for use of Tenecteplase in stroke therapy.  
  • Alteplase
  • Best Practices
  • CME Activities
  • Critical Care
  • Emergency
  • Nursing Continuing Education
  • Stroke
  • Nursing Education Hours
  • Participation
$0.00
Evidence has shown that the benefits of IV tPA and thrombectomy in acute ischemic stroke are time-dependent.  Therefore, AHA guidelines have made certain recommendations regarding door-to-needle and door-to-groin puncture time.  Despite this, the majority of acute ischemic patients who receive tPA and thrombectomy are not treated within this time.  Stroke quality programs have been shown to improve doo-to-needle and door-to-groin puncture time, thus improving outcomes in the care of acute ischemic stroke.  This program will discuss best practices in acute stroke care to assist healthcare pr
  • Alteplase
  • Best Practices
  • Critical Care
  • Emergency
  • Epilepsy
  • Neurology
  • Nursing Continuing Education
  • Stroke
  • Tenecteplase
  • Thrombolytics
  • Nursing Contact Hours
$0.00
Join TeleSpecialists Dr. Theresa Sevilis, board certified vascular neurologist to review the American Heart Association Guidelines for the Early Management of Patients with Acute Ischemic Stroke.  Dr. Sevilis will discuss the indications, relative contraindications, and absolute contraindications for thrombolytics, provide cases for review, and discuss how to use the Guidelines in the decision making process.  She will highlight the most commonly asked questions surrounding thrombolytic administration and discuss the new utilization of tenecteplase in place of alteplase.